Cart
×
CureDuchenne Cares Webinar: Optimizing Cardiac Outcomes in Duchenne
CureDuchenne and Andreas S. Barth, MD, PhD, FAHA, for a community webinar about Optimizing Cardiac Outcomes in Duchenne. Watch HERE
CureDuchenne Announces Fuerza 2025: A Landmark Conference in Mexico City on October 25 Focused on Duchenne and Becker Muscular Dystrophy
Full-Day Conference Will Bring Education, Support, and Connection to Families and Healthcare Providers Serving the Duchenne and Becker Community Newport Beach, Calif., September 18, 2025 — CureDuchenne, a global leader […]
Gear Up and Give Back with Violent Gentlemen Hockey Club
Limited-Edition Violent Gentlemen Hockey Club Tees Benefiting the CureDuchenne. Your purchase makes a difference.Every tee supports CureDuchenne’s mission to improve the lives of everyone affected by Duchenne muscular dystrophy—by accelerating […]
ITF Therapeutics shares publication of long-term data showing givinostat can delay loss of functional abilities in Duchenne
Results published in the Annals of Clinical and Translational Neurology show that long-term treatment with givinostat, a histone deacetylase (HDAC) inhibitor, in combination with corticosteroids, delayed disease progression in ambulant individuals with […]
REGENXBIO AFFINITY DUCHENNE: Trial of Investigational RGX-202 Gene Therapy
In this webinar, Dr. Naz Dastgir, Executive Medical Director and Clinical Development Lead for RGX-202 at REGENXBIO, shared information on the active and enrolling AFFINITY DUCHENNE trial and how families […]
Solid Biosciences announced a widely anticipated update on their INSPIRE DUCHENNE Phase 1/2 clinical trial of SGT-003
Solid Biosciences announced a widely anticipated update on their INSPIRE DUCHENNE Phase 1/2 clinical trial of SGT-003, their investigational micro-dystrophin gene therapy for Duchenne muscular dystrophy. What this means for […]
Entrada Therapeutics doses first participant in Exon 44 skipping program; provides updates to other exon-skipping programs
Entrada Therapeutics, which received early funding from CureDuchenne, has provided updates on the status of several exon skipping programs. We are pleased to share that they have dosed the first […]
Dyne Therapeutics granted Breakthrough Therapy Designation for exon-51skipping therapeutic, DYNE-251
CureDuchenne was an early investor in Dyne Therapeutics in 2020, and congratulates the company for receiving Breakthrough Therapy Designation from the US FDA for DYNE-251, their exon 51-skipping agent for the treatment of […]
ELEVIDYS UPDATE
Breaking News: Sarepta to resume shipments of ELEVIDYS for ambulatory individuals with Duchenne 07/28/25 5:09 PM EDT We are pleased to report that the US FDA has recommended that Sarepta […]